{"schema_version":"secwatch.filing_event.v1","accession":"0001553350-26-000007","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.213039+00:00","generated_at":"2026-05-16T01:13:59.187501+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"confidence":"high","headline":"The Oncology Institute appoints Kim Tzoumakas to Board of Directors","bullets":["Appointed Kim Tzoumakas, CEO of VytlOne National Pharmacy Services, to board effective Feb. 23, 2026.","Ms. Tzoumakas previously led 21st Century Oncology through a turnaround and strategic sale; serves on multiple healthcare boards.","She will receive $75k annual cash retainer paid quarterly plus restricted stock units for board service.","She was not initially assigned to any board committees; term expires at 2027 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001553350-26-000007","json":"https://secwatch.observer/filing/0001553350-26-000007.json","markdown":"https://secwatch.observer/filing/0001553350-26-000007.md","text":"https://secwatch.observer/filing/0001553350-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000155335026000007/0001553350-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000155335026000007/toi_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:13:59.187501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}